Amarin Corp Plc (AMRN)

[retinadoc]

Killing MO idiocy with the smoking study. I think there is potentially a significant finding buried in Bhatt's study. Instead of comparing the smoking group to placebo, compare it to a matched cohort of nonsmokers who were taking Vascepa. Smoking now is the only variable. If the unquestioned increase in smoking related CV events is again significantly negated, it can only be explained by the efficacy of Icosapent Ethyl and not that the placebo group was made more susceptible.

RTC purists will argue that using a historical control is not acceptable. However, the numbers are very large in the Vascepa treated cohorts, and CV risk associated with smoking has been studied endlessly and has widespread acceptance.

Thoughts?